Following strong growth across its drug portfolio in the first half year, AstraZeneca Plc has upgraded its revenue and profit forecast for 2024 and reaffirmed its target for revenue at the end of the decade. Pascal Soriot, the chief executive, told journalists on 25 July that the company expects to deliver a mid-teen percentage increase in revenue and core earnings per share this year and a revenue figure of $80 billion by 2030. The 2030 forecast would represent a significant increase from the $45.8 billion delivered in 2023.
